whats up with these analyst, i'm starting to think they are all idiots!
300 + coming next
Bio tech M & A is highly likely to swallow up ICPT soon as they are in a 10billion+ drug in the making and big bio's are swallowing these companies up quickly in the 5 to 15 billion range.
100 + coming
this close to 100................will break 100 just for the CNBC crew to comment on that!
results were good as company said considering a patient size of only 30, the miss on CDR-SB is likely a skewed result of being such a small group for the study as shown with the MMSE results of 6mg falling right in the previous results at 1, 3 and 10 mg. I can see why the company is continuing phase 3 with a large scale study, results were good overall.
thats very odd that the MMSE at 6 mg would be off but on the CDR-SB would fall right in line with the results of the march studies. Makes you wonder with such a small group, something scewed that test results on MMSE. The large phase 3 studies are likely to show that the MMSE and CDR-SB falls into scale with various doses and that MMSE results had something that screwed it with such a small group.
"Biogen jumped into a pair of phase 3 trials testing two different doses without stopping at phase 2."
that tells me a lot right there!
Valuable franchise in liver desease drugs about to get bought out here. Likely buyer is Gilead who is flush with cash and in need of the next 10 billion dollar drug in phase 3.
That news should have RNF up as consolidation is the name of the game and RNF is up for sale!
would create a powerhouse in diseases that affect the liver and with ICPT the drug to repair it from the damage done by the diseases that they already are big in. Perfect fit!
Doubt they will wait as others are starting to buy up the 5 to 10 billion size bio techs that have the potential for major blockbuster drugs of sales of more than 10 billion a year when approved.
The fact that there is not a lot of excitement going on here leads me to think this will surprise with great results and we will see a big move up. Company's announcement to spend 2.5 billion on phase 3 trials wouldn't happen on lukewarm results.
Read that too, that to me would dramatically help in getting results that a more realistic to benefits. I was wondering how the 1, 3 and 10 mg dose performed at the 6 months of their trial to compare if the drug performs more in the last 6 months vs the first 6 months. There was concern that the results were similar to placebo at that point. Could also differentiate itself after 6 months as placebo group continues to deteriorate more quickly too.
410 breakout and it will run
any results of their hiring of Morgan Stanley for strategic alternatives. When you say in your conference call your will have something the end of June you better have something!